← SynDRA

DACOMITINIB ANHYDROUS

SynDRA canonical compound SYN0033402 — structure-anchored drug synonym record

All known targets

• EGFR
• ERBB2
• ERBB4
• GAK
• JAK3
• LCK
• RIPK2
• RIPK3
• SRC

Mechanisms of action (all sources)

• EGFR INHIBITOR
• Epidermal growth factor receptor erbB1 inhibitor
• ERBB2 INHIBITOR
• Receptor protein-tyrosine kinase erbB-2 inhibitor
• ERBB4 INHIBITOR
• Receptor protein-tyrosine kinase erbB-4 inhibitor
• ERBB4 ANTAGONIST
• ERBB2 ANTAGONIST
• EGFR ANTAGONIST

Drug classes

• Tyrosine Kinase Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 11511120
• ChEMBL: CHEMBL2110732
• DrugBank: DB11963
• ChEBI: CHEBI:132268
• KEGG: D09883
• RxNorm: 2058848
• PDB: 1C9
• Wikipedia: Dacomitinib
• TTD: D06XXH

Synonyms

• dacomitinib
• dacomitinib hydrate
• vizimpro
• PF-00299804-03
• PF-00299804
• PF-299
• PF-299804
• PF-804
• Pf-00299804
• Dacomitinib
• PF299804
• Dacomitinib (PF299804, PF299)
• (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
• (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
• Dacomitinib (PF299804)
• 2XJX250C20
• PF 00299804-03
• Dacomitinib (INN)
• (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
• DACOMITINIB [INN]
• PF-299804 (Dacomitinib PF-00299804)
• (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
• Dacomitinib [USAN:INN]
• dacomitinibum
• UNII-2XJX250C20
• PF299
• (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
• DACOMITINIB [WHO-DD]
• MLS006011275
• GTPL7422
• CHEMBL2110732
• CHEBI:91466
• DTXSID50149493
• EX-A030
• CHEBI:132268
• BDBM112499
• Dacomitinib (PF-00299804)
• AMY21292
• BCP02530

Reported adverse events

• Alopecia
• Asthenia
• Conjunctivitis
• Dermatitis
• Dry skin
• Mouth ulceration
• Nausea
• Paronychia
• Pruritus
• Rash
• Stomatitis
• Decreased appetite